921 related articles for article (PubMed ID: 26875002)
1. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
2. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.
Weinreb RN; Liebmann JM; Martin KR; Kaufman PL; Vittitow JL
J Glaucoma; 2018 Jan; 27(1):7-15. PubMed ID: 29194198
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.
Medeiros FA; Martin KR; Peace J; Scassellati Sforzolini B; Vittitow JL; Weinreb RN
Am J Ophthalmol; 2016 Aug; 168():250-259. PubMed ID: 27210275
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.
Liu JHK; Slight JR; Vittitow JL; Scassellati Sforzolini B; Weinreb RN
Am J Ophthalmol; 2016 Sep; 169():249-257. PubMed ID: 27457257
[TBL] [Abstract][Full Text] [Related]
5. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL;
Br J Ophthalmol; 2015 Jun; 99(6):738-45. PubMed ID: 25488946
[TBL] [Abstract][Full Text] [Related]
6. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
7. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.
Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP;
Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843
[TBL] [Abstract][Full Text] [Related]
8. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
[TBL] [Abstract][Full Text] [Related]
9. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
Hoy SM
Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
[TBL] [Abstract][Full Text] [Related]
10. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
[TBL] [Abstract][Full Text] [Related]
11. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
[TBL] [Abstract][Full Text] [Related]
12. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
Ophthalmology; 2020 Dec; 127(12):1627-1641. PubMed ID: 32544560
[TBL] [Abstract][Full Text] [Related]
13. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
Susanna R; Sheu WP;
Clin Ther; 2004 May; 26(5):755-68. PubMed ID: 15220019
[TBL] [Abstract][Full Text] [Related]
14. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
Fingeret M; Gaddie IB; Bloomenstein M
Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
[TBL] [Abstract][Full Text] [Related]
15. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
16. Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
Kawase K; Vittitow JL; Weinreb RN; Araie M;
Adv Ther; 2016 Sep; 33(9):1612-27. PubMed ID: 27457469
[TBL] [Abstract][Full Text] [Related]
17. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
Diestelhorst M; Larsson LI;
Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
[TBL] [Abstract][Full Text] [Related]
19. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
Kaufman PL
Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
[TBL] [Abstract][Full Text] [Related]
20. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
Diestelhorst M; Larsson LI;
Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]